

# RÃ³bert SzÃ¡sz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7824074/publications.pdf>

Version: 2024-02-01

19  
papers

719  
citations

933447

10  
h-index

677142

22  
g-index

27  
all docs

27  
docs citations

27  
times ranked

866  
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating microRNA sequencing revealed miRNome patterns in hematology and oncology patients aiding the prognosis of invasive aspergillosis. <i>Scientific Reports</i> , 2022, 12, 7144.	3.3	2
2	Ibrutinib-induced acute kidney injury via interstitial nephritis. <i>Renal Failure</i> , 2021, 43, 335-339.	2.1	7
3	Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies. <i>Pathology and Oncology Research</i> , 2021, 27, 1609742.	1.9	4
4	Screening and monitoring of the <i>BTK</i> <sup>C481S</sup> mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy. <i>British Journal of Haematology</i> , 2021, 194, 355-364.	2.5	13
5	Free circulating microRNAs support the diagnosis of invasive aspergillosis in patients with hematologic malignancies and neutropenia. <i>Scientific Reports</i> , 2020, 10, 16532.	3.3	6
6	Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020, 95, 604-611.	4.1	12
7	Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia. <i>Platelets</i> , 2019, 30, 836-843.	2.3	18
8	Novel MASP-2 inhibitors developed via directed evolution of human TFPI1 are potent lectin pathway inhibitors. <i>Journal of Biological Chemistry</i> , 2019, 294, 8227-8237.	3.4	11
9	Selectin Expression is Influenced by Phosphatase Activity in Chronic Lymphocytic Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 149-157.	1.5	7
10	Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILIL Study). <i>Pathology and Oncology Research</i> , 2019, 25, 535-540.	1.9	0
11	MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked. <i>Scientific Reports</i> , 2016, 6, 31877.	3.3	108
12	Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment. <i>Platelets</i> , 2013, 24, 486-492.	2.3	8
13	Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 10498-10503.	7.1	196
14	Selective Inhibition of the Lectin Pathway of Complement with Phage Display Selected Peptides against Mannose-Binding Lectin-Associated Serine Protease (MASP)-1 and -2: Significant Contribution of MASP-1 to Lectin Pathway Activation. <i>Journal of Immunology</i> , 2010, 185, 4169-4178.	0.8	69
15	Bortezomib+Chemotherapy Based Salvage Combinations in Refractory AML, Preliminary Results. <i>Blood</i> , 2008, 112, 4000-4000.	1.4	0
16	Coated-platelets retain amyloid precursor protein on their surface. <i>Platelets</i> , 2006, 17, 56-60.	2.3	41
17	Role of Mitochondrial Permeability Transition Pore in Coated-Platelet Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 467-471.	2.4	109
18	COAT platelets. <i>Current Opinion in Hematology</i> , 2003, 10, 351-355.	2.5	34

#	ARTICLE	IF	CITATIONS
19	Thrombospondin and fibrinogen bind serotonin-derivatized proteins on COAT-platelets. Blood, 2002, 100, 2827-2831.	1.4	62